Bio Green Med Solution, Inc. (BGMS) 股票分析

公司概述

Bio Green Med Solution, Inc. primarily engages in the distribution, trading, and installation of protective and fire safety materials, equipment, and systems, while simultaneously conducting research and development in the pharmaceutical sector. The company operates within the Healthcare sector, specifically the Biotechnology industry, a classification that defines its focus on biological products and medical technologies rather than traditional manufacturing or services. With a market capitalization of $5.57 million and trailing twelve-month revenue of $747,000, the company maintains a minimal operational footprint with an employee count listed as N/A. These valuation and revenue figures indicate that Bio Green Med Solution, Inc. is a micro-cap entity with limited scale, suggesting high volatility and significant risk relative to larger peers, as its financial resources are constrained by a very small total asset base.

财务健康

The company reported a revenue of $747,000 over the trailing twelve months, yet it recorded a net income of -$14,092,000 and an EBITDA of -$8,422,000, revealing a severe structural disconnect where operating expenses vastly outweigh all revenue generated. The free cash flow stands at -$10,077,875, which indicates a substantial cash outflow that significantly erodes the company's financial flexibility and limits its ability to fund organic growth without external capital injections. Margins are deeply negative, with a gross margin of -90.1%, an operating margin of -162.5%, and a profit margin of 0.0%, collectively signaling that the cost of goods sold and operating expenses are more than double the revenue, a typical characteristic of early-stage biotechnology firms but one that poses a severe sustainability challenge. Regarding liquidity and leverage, the company holds $3.50 million in cash against a negligible debt level of $2,000, resulting in a debt-to-equity ratio of 0.03, which suggests a balance sheet that is technically unleveraged but relies entirely on its cash reserves to cover burn rates. The current ratio is 4.70, indicating a strong ability to meet short-term obligations with current assets, although this liquidity does not offset the persistent operational losses. Return on Equity is -128.4% and Return on Assets is -85.8%, metrics that reveal management has been ineffective at generating positive returns on the capital invested, instead accelerating the dilution of shareholder value through continuous cash consumption.

估值评估

Trailing P/E and forward P/E ratios are both listed as N/A due to the company's lack of positive earnings, meaning traditional earnings-based valuation multiples are inapplicable and do not provide insight into expected earnings trajectories or future profitability. The price-to-book ratio is 0.80, which indicates that the market values the company at 80% of its net asset value, suggesting the market is pricing in significant risks regarding the viability of its business model and the realization of its assets. Alternative valuation metrics show a price-to-sales ratio of 7.46 and an EV/EBITDA of -0.25; the high multiple relative to sales implies that investors are willing to pay a premium for the company's intellectual property or potential pipeline despite the negative EBITDA, while the negative EV/EBITDA reflects the heavy cash burn relative to enterprise value. The stock has experienced extreme price volatility, trading between a 52-week low of $0.73 and a 52-week high of $100.80, with the current price effectively sitting within this broad range where the low represents a massive discount and the high represents a substantial expansion from the baseline. The beta value of -0.53 is a rare negative coefficient, indicating that the stock's price movements are inversely correlated with the broader market, behaving counter-cyclically and offering a unique risk profile distinct from standard equities.

Growth & Income

Revenue growth and earnings growth rates are both listed as N/A, preventing a direct comparison to determine if earnings are growing faster or slower than revenue, though the absolute figures suggest the company is currently in a phase of negative or undefined growth. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash is being retained and reinvested into research and development rather than distributed to shareholders. The absence of dividend payments aligns with the company's biotechnology business model, where capital allocation is prioritized toward sustaining operations and advancing pharmaceutical research rather than providing income to investors. In summary, the overall growth and income profile is characterized by a complete lack of current profitability, zero dividend income, and a reliance on cash reserves to fund operations in a highly competitive healthcare environment.